legend biotech - LEGN

LEGN

Close Chg Chg %
18.20 -0.04 -0.22%

Pre-Market

18.16

-0.04 (0.22%)

Volume: 2.18M

Last Updated:

Apr 10, 2026, 4:00 PM EDT

Company Overview: legend biotech - LEGN

LEGN Key Data

Open

$18.17

Day Range

17.76 - 18.29

52 Week Range

16.25 - 45.30

Market Cap

$3.37B

Shares Outstanding

184.94M

Public Float

178.18M

Beta

0.08

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.62

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.32M

 

LEGN Performance

1 Week
 
0.00%
 
1 Month
 
-3.15%
 
3 Months
 
-17.98%
 
1 Year
 
-43.25%
 
5 Years
 
-30.15%
 

LEGN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 19
Full Ratings ➔

About legend biotech - LEGN

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

LEGN At a Glance

Legend Biotech Corp.
2101 Cottontail Lane
Somerset, New Jersey 08873
Phone 1-737-317-5050 Revenue 1.03B
Industry Pharmaceuticals: Major Net Income -297,584,957.55
Sector Health Technology 2025 Sales Growth 64.387%
Fiscal Year-end 12 / 2026 Employees 2,900
View SEC Filings

LEGN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.884
Price to Book Ratio 4.012
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -32.185
Enterprise Value to Sales 3.366
Total Debt to Enterprise Value 0.119

LEGN Efficiency

Revenue/Employee 355,731.437
Income Per Employee -102,615.503
Receivables Turnover 4.122
Total Asset Turnover 0.606

LEGN Liquidity

Current Ratio 1.96
Quick Ratio 1.909
Cash Ratio 1.491

LEGN Profitability

Gross Margin 57.527
Operating Margin -13.267
Pretax Margin -27.466
Net Margin -28.846
Return on Assets -17.485
Return on Equity -29.137
Return on Total Capital -21.019
Return on Invested Capital -24.041

LEGN Capital Structure

Total Debt to Total Equity 41.283
Total Debt to Total Capital 29.22
Total Debt to Total Assets 23.862
Long-Term Debt to Equity 8.702
Long-Term Debt to Total Capital 6.159
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Legend Biotech - LEGN

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
116.87M 285.14M 627.56M 1.03B
Sales Growth
+69.57% +143.99% +120.08% +64.39%
Cost of Goods Sold (COGS) incl D&A
83.66M 164.66M 258.07M 438.16M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
18.37M 20.45M 23.37M 28.98M
Depreciation
15.90M 18.53M 21.44M 28.98M
Amortization of Intangibles
- 2.47M 1.92M 1.93M
COGS Growth
- +96.84% +56.72% +69.78%
Gross Income
33.21M 120.48M 369.49M 593.47M
Gross Income Growth
- +262.77% +206.68% +60.62%
Gross Profit Margin
+28.42% +42.25% +58.88% +57.53%
2022 2023 2024 2025 5-year trend
SG&A Expense
490.72M 562.69M 674.79M 729.32M
Research & Development
335.25M 382.22M 413.75M 415.80M
Other SG&A
155.47M 180.48M 261.04M 313.53M
SGA Growth
+9.17% +14.67% +19.92% +8.08%
Other Operating Expense
- - 4.43M 1.00M
-
Unusual Expense
- - (21.48M) 85.09M
-
EBIT after Unusual Expense
(436.03M) (527.30M) (309.73M) (136.86M)
Non Operating Income/Expense
1.62M 28.98M 173.14M (125.03M)
Non-Operating Interest Income
8.17M 54.49M 61.23M 40.21M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
10.78M 21.79M 21.63M 21.46M
Interest Expense Growth
+1,096.54% +102.11% -0.77% -0.78%
Gross Interest Expense
10.78M 21.79M 21.63M 21.46M
Interest Capitalized
- - - -
-
Pretax Income
(445.19M) (520.12M) (158.21M) (283.35M)
Pretax Income Growth
-9.19% -16.83% +69.58% -79.09%
Pretax Margin
-380.94% -182.41% -25.21% -27.47%
Income Tax
624.26K (1.86M) 18.90M 14.24M
Income Tax - Current - Domestic
400.52K 511.00K 997.50K 4.51M
Income Tax - Current - Foreign
223.73K (2.38M) 17.90M 9.73M
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(445.82M) (518.25M) (177.11M) (297.58M)
Minority Interest Expense
- - - -
-
Net Income
(445.82M) (518.25M) (177.11M) (297.58M)
Net Income Growth
-10.32% -16.25% +65.82% -68.02%
Net Margin Growth
-381.48% -181.75% -28.22% -28.85%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(445.82M) (518.25M) (177.11M) (297.58M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(445.82M) (518.25M) (177.11M) (297.58M)
EPS (Basic)
-2.8031 -2.9432 -0.9686 -1.6145
EPS (Basic) Growth
+2.30% -5.00% +67.09% -66.68%
Basic Shares Outstanding
159.04M 176.08M 182.85M 184.32M
EPS (Diluted)
-2.8031 -2.9432 -0.9686 -1.6145
EPS (Diluted) Growth
+2.30% -5.00% +67.09% -66.68%
Diluted Shares Outstanding
159.04M 176.08M 182.85M 184.32M
EBITDA
(439.14M) (421.76M) (286.36M) (107.88M)
EBITDA Growth
-15.38% +3.96% +32.11% +62.32%
EBITDA Margin
-375.76% -147.91% -45.63% -10.46%

Snapshot

Average Recommendation BUY Average Target Price 56.611
Number of Ratings 19 Current Quarters Estimate 0.047
FY Report Date 06 / 2026 Current Year's Estimate 0.238
Last Quarter’s Earnings N/A Median PE on CY Estimate N/A
Year Ago Earnings -0.81 Next Fiscal Year Estimate 0.982
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 18 18
Mean Estimate 0.05 0.07 0.24 0.98
High Estimates 0.21 0.19 0.79 1.83
Low Estimate -0.07 -0.02 -0.20 0.12
Coefficient of Variance 170.00 83.71 96.18 45.59

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 15 15 18
OVERWEIGHT 2 2 2
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Legend Biotech in the News